Full-Time

Specialty Representative

Migraine

Posted on 9/3/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$78.5k - $141k/yr

+ Short-term incentive program

Cleveland, OH, USA

Remote

Candidates should live within a reasonable distance of Cleveland.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Branding/Brand Strategy
CRM
Marketing

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree in health, sciences, pharmacy, or a business-related field, or equivalent industry experience in lieu of the degree.
  • At least five years of equivalent industry experience when substituting for the bachelor's degree, with three or more years within the pharmaceutical, health, or science industry preferred.
  • A high school diploma or GED when using the equivalent-industry-experience pathway.
  • A proven track record of leadership success and solid presentation skills.
  • Strong business acumen and proficient use of business tools.
  • Strategic and critical-thinking capabilities.
  • Ability to identify customer styles and behaviors and adapt all aspects of the selling approach.
  • Ability to operate effectively in a matrix environment.
  • Ability to satisfy applicable health care industry representative credentialing requirements and remain in good standing or eligible to obtain the credentials.
  • A valid driver's license, successful completion of a pre-employment drug screening test, and compliance with safe-driving requirements.
Responsibilities
  • Deliver sales performance, brand key performance indicators, financial targets, and marketing objectives to meet or exceed objectives.
  • Create pre-call plan objectives and execute post-call evaluations to continuously improve sales performance.
  • Handle objections, misunderstandings, and concerns, and gain logical and reasonable calls to action to close on every sales call.
  • Serve customer needs and expectations and address challenges to build trusted customer relationships and achieve win-win agreements between AbbVie and customers.
  • Develop and execute a call plan that achieves set call metrics and optimizes coverage and frequency for key customers to maximize access and sales opportunities.
  • Build understanding of customer needs and expectations, the territory market landscape, competitors, market segments and dynamics, accounts, disease, products, clinical knowledge, and sales expertise.
  • Share market intelligence with the in-field team, brand team, and sales manager to achieve alignment, anticipate environmental changes and challenges, and optimize brand strategy and execution.
  • Differentiate AbbVie's value proposition with assigned health care providers.
  • Identify, develop, and maintain disease-state experts and speakers or advocates to maximize brand performance.
Desired Qualifications
  • Three or more years of experience within the pharmaceutical, health, or science industry.
  • A proven track record of sales performance within the respective therapeutic area.
  • Commercial pharmaceutical industry experience, such as physician or account-based selling, training, managed health care, or marketing.
  • In-depth scientific, therapeutic, product, and competitive knowledge, with recognition as an expert resource by relevant stakeholders.
  • English language proficiency verbally and in writing for non-English-speaking countries.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $16.99 billion, up 10.2%, and adjusted EPS reached $3.65.
  • FDA approved Decnupaz in May 2026, AbbVie’s first hematology ADC.
  • European approvals for Rinvoq in vitiligo and alopecia expand 2026 commercial reach.

What critics are saying

  • Imbruvica faced Medicare price cuts in 2026, accelerating oncology erosion and reimbursement pressure.
  • Oncology revenue fell 2.4% in Q2 2026 as Imbruvica dropped 29.4%.
  • Skyrizi-Rinvoq concentration leaves AbbVie vulnerable if one safety signal emerges.

What makes AbbVie unique

  • AbbVie’s Skyrizi and Rinvoq generated enough growth to replace Humira by 2025.
  • AbbVie now pairs immunology scale with oncology assets like Epkinly, Emrelis, and Decnupaz.
  • Apogee’s 2026 deal adds late-stage IL-13 and TSLP antibodies for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.

Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.